A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors Vertex Pharmaceuticals
- 04 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 02 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.